Cost effectiveness of therapies for atrial fibrillation: A review

PharmacoEconomics

Volumn 18, Issue 4, 2000, Pages 317-333

  Teng, M P ^a   Catherwood, E ^a   Melby, D P ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; DISOPYRAMIDE; DOFETILIDE; FLECAINIDE; IBUTILIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; WARFARIN;

ARRHYTHMOGENESIS; CARDIOVERSION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DYSPNEA; FATIGUE; HEART ATRIUM FIBRILLATION; HEART MUSCLE FIBROSIS; HEART PALPITATION; HUMAN; LUNG DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCREENING; SINUS RHYTHM; TELEMETRY; THORAX PAIN; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0033770228     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200018040-00002     Document Type: Review

References (123)

1. Management of patients with atrial fibrillation. A statement for healthcare professionals from the subcommittee on electrocardiography and electrophysiology. American Heart Association
2. Management of atrial fibrillation in adults: Prevention of thromboembolism and symptomatic treatment
3. Atrial fibrillation: A review of mechanism, etiology, and therapy
4. Prevalencem, age distribution, and gender of patients with atrial fibrillation. Analysis and implications
5. Secular trends in the prevalence of atrial fibrillation: The Framingham study
6. The natural history of lone atrial fibrillation. A population-based study over three decades
7. Experimental observations on atrial fibrillation
8. Atrial fibrillation begets atrial fibrillation: A study in awake chronically instrumented goats
9. Paroxysmal atrial fibrillation. A common but neglected entity
10. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic cardiomyopathy
11. Functional capacity before and after cardioversion of atrial fibrillation: A controlled study
12. Hemodynamic changes after cardioversion of chronic atrial fibrillation
13. Atrial fibrillation as an independent risk factor for stroke: The Framingham study
14. Newly diagnosed atrial fibrillation and acute stroke
15. Atrial fibrillation and stroke. Three new studies, three remaining questions
16. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials
17. Role of anticoagulant therapy in atrial fibrillation
18. Artithrombotic therapy in atrial fibrillation
19. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis
20. Transoesophageal echocardiography to assess embolic risk in patients with atrial fibrillation
21. Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with non-valvular atrial fibrillation
22. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk
23. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin Stroke Prevention in Atrial Fibrillation III study
24. Stroke with intermittent atrial fibrillation: Incidence and predictors during aspirin therapy
25. Risk for clinical thromboembolism associated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours
26. Cost-effective strategies in the acute management of atrial fibrillation
27. Likelihood of spontaneous conversion of atrial fibrillation to sinus rhythm
28. Management of atrial fibrillation: Simplicity surrounded by controversy
29. Should all patients undergo transesophageal echocardiography before electrical cardioversion of atrial fibrillation
30. Accuracy of transesophageal echocardiography for identifying left atrial thrombi
31. Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: Final results of a prospective 4.5-year study
32. Framing and designing the cost-effectiveness analysis
33. Decision analysis
34. A clinician's guide to cost-effectiveness analysis
35. Cost-effectiveness analysis in heart disease, Part I: General principles
36. Markov models in medical decision making: A practical guide
37. Utility approach to measuring health-related quality of life
38. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life
39. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines and economic evaluations
40. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation
41. Reflecting uncertainty in cost-effectiveness analysis
42. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study
43. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation
44. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study
45. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators
46. Stroke Prevention in Atrial Fibrillation Study. Final results
47. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
48. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective
49. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation
50. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke
51. Making decisions about antithrombotic therapy in heart disease: Decision analytic and cost-effectiveness issues
52. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation
53. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation
54. Optimal oral anticoagulation therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
55. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range
56. Is warfarin underused in the treatment of elderly persons with atrial fibrillation?
57. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation
58. Comparison of an anticoagulation clinic with usual medical care
59. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention
60. Hemorrhagic complications of anticoagulant treatment
61. Bleeding during antithrombotic therapy in patients with atrial fibrillation
62. Efficacy of ibutilide for termination of atrial fibrillation and flutter
63. Ibutilide: A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation
64. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment
65. Quinidine versus propafenone for conversion of atrial fibrillation to sinus rhythm
66. Quinidine
67. Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation
68. Chronic atrial fibrillation. Long-term results of direct current conversion
69. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: A meta-analysis
70. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group
71. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators
72. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: A multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group
73. Dofetilide: A review of its use in atrial fibrillation and atrial flutter
74. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide
75. Amiodarone: Reevaluation of an old drug
76. Amiodarone in restoration and maintenance of sinus, rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current cardioversion
77. Recent national patterns of warfarin use in atrial fibrillation
78. Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision
79. Drugs for conversion of atrial fibrillation
80. Treatment strategies for atrial fibrillation
81. Acute treatment of atrial fibrillation
82. Cost-effective management of acute atrial fibrillation: Role of rate control, spontaneous conversion, medical and direct current cardioversion, transesophageal echocardiography, and antiembolic therapy
83. Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter
84. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation
85. Ibutilide
86. Managing chronic atrial fibrillation: A Markov decision analysis comparing warfarin, quinidine, and low-dose amiodarone
87. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation. A decision analysis
88. Therapeutic strategies for atrial fibrillation. The value of decision analysis
89. Adverse effects of low dose amiodarone: A meta-analysis
90. Amiodarone pulmonary toxicity
91. Finding what you seek: Analyzing therapies for nonvalvular atrial fibrillation
92. Proarrhythmia during drug treatment of supraventricular tachycardia: Paradoxical risk of sinus rhythm for sudden death
93. Risk of initiating antiarrhythmic drug therapy for atrial fibrillation in patients admitted to a university hospital
94. Atrial Fibrillation Follow-Up Investigation of Rhythm Management-the AFFIRM Study design
95. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial
96. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation
97. Proarrhythmia in patients treated for atrial fibrillation or flutter
98. Proarrhythmia
99. Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications
100. Antiarrhythmic drug initiation in patients with atrial fibrillation
101. Cost-effectiveness of inpatient initiation of antiarrhythmic therapy for supraventricular tachycardias
102. Risks of initiating therapy with sotalol for treatment of atrial fibrillation
103. Perspectives and controversies in atrial fibrillation
104. Anticoagulation for cardioversion of atrial arrhythmias
105. Exclusion of atrial thrombus by transesophageal echocardiography does not preclude embolism after cardioversion of atrial fibrillation
106. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: A decision analytic model for patients admitted to the hospital with atrial fibrillation
107. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: Should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis
108. Assessment of cardioversion using transesophageal echocardiography multicenter study
109. Amiodarone to prevent recurrences of atrial fibrillation
110. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia
111. Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: Protagonist
112. The case for inpatient initiation of antiarrhythmic therapy
113. The role of nonpharmacologic therapies for the treatment of atrial fibrillation
114. Atrial fibrillation: Nonpharmacologic approaches
115. Atrioventricular nodal modification and atrioventricular junctional ablation for control of ventricular rate in atrial fibrillation
116. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation
117. Role of catheter ablation for atrial fibrillation
118. Initial experience with an implantable human atrial defibrillator
119. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance
120. Postoperative atrial fibrillation
121. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery
122. Atrial fibrillation: The epidemic of the new millennium
123. Atrial fibrillation trials: Will they teach us what we need to know?